Portfolio record
Luang Pharma is establishing a pharmaceutical manufacturing facility in the Boten Economic Zone, Lao PDR. The portfolio below is being prepared for submission and registration; it is not an offer of supply and no line is registered or available yet.
About Silver sulfadiazine
Silver sulfadiazine is a topical sulfonamide antibacterial compound. Its mechanism involves the gradual release of silver ions that bind to microbial DNA and cellular proteins, alongside the competitive inhibition of para-aminobenzoic acid by the sulfadiazine moiety. Developed in the 1960s, it is recognised on the WHO Model List of Essential Medicines and detailed in the major pharmacopoeias. It is globally formulated as a one percent topical cream.
This text describes the substance in general terms using publicly available pharmacological references. It is not labelling for any Luang Pharma product, and no Luang Pharma product containing this substance is registered or available for supply.
Brand name
Brand name: to be confirmed on registration. The line is identified here by its international non-proprietary name.
Dosage form
The one percent cream preparation provides a continuous release of the active ions and molecules from a semi-solid dermal base.
Regulatory position
Before this line can be supplied: Lao FDD registration, GMP batch records, validated method, stability program, QA release and approved trilingual labeling required.
This page states the product identity only. It carries no information about medical use, and it is not a substitute for approved labelling or the judgement of a qualified healthcare professional.
Requesting documentation
Regulatory, technical and distribution enquiries are answered at info@luangpharma.com. Please state the country, your company, the portfolio reference above and the documentation you need.
